[1] Barber SC, Mellor H, Gampel A, et al. S1P and LPA trigger Schwann cell actin changes and migration[J]. Eur J Neurosci, 2004, 19(12):3142-3150. [2] Okabe K, Hayashi M, Fujii M, et al. Mutations of lysophosphatidic acid receptor genes in human osteosarcoma cells[J]. Pathobiology, 2010, 77(5):278-282. [3] Kato K, Fukui R, Okabe K, et al. Constitutively active lysophosphatidic acid receptor-1 enhances the induction of matrix metalloprotei-nase-2[J]. Biochem Biophys Res Commun, 2012, 417(2):790-793. [4] Hayashi M, Okabe K, Kato K, et al. Differential function of lysophosphatidic acid receptors in cell proliferation and migration of neuroblastoma cells[J]. Cancer Lett, 2012, 316(1):91-96. [5] Kato K, Yoshikawa K, Tanabe E, et al. Opposite roles of LPA(1)and LPA(3)on cell motile and invasive activities of pancreatic cancer cells[J]. Tumour Biol, 2012, 33:1739-1744. [6] Marshall JC, Collins JW, Nakayama J, et al. Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer[J]. J Natl Cancer Inst, 2012, 104(17):1306-1319. [7] Anliker B, Chun J. Lysophospholipid G protein-coupled receptors[J]. J Biol Chem, 2004, 279:20555-20558. [8] Shida D, Kitayama J, Yamaguchi H, et al. Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells[J]. Exp Cell Res, 2004, 301(2):168-178. [9] Hecht JH, Weiner JA, Post SR, et al. Ventricular zone gene-1(vzg-1)encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex[J]. J Cell Biol, 1996, 135(4):1071-1083. [10] Contos JJ, Ishii I, Chun J. Lysophosphatidic acid receptors[J]. Mol Pharmacol, 2000, 58(6):1188-1196. [11] An S, Dickens MA, Bleu T, et al. Molecular cloning of the human Edg2 protein and its identification as a functional cellular receptor for lysophosphatidic acid[J]. Biochem Biophys Res Commun, 1997, 231(3):619-622. [12] Ward Y, Lake R, Yin JJ, et al. LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells[J]. Cancer Res, 2011, 71:7301-7311. [13] Lin ME, Herr DR, Chun J. Lysophosphatidic acid(LPA)receptors:signaling properties and disease relevance[J]. Prostaglan-dins & Other Lipid Mediators, 2010, 91(3-4):130-138. [14] Saulnier-Blache JS. Lysophosphatidic acid:a “bioactive” phospholipid[J]. Medecine Sciences:M/S, 2004, 20:799-803. [15] Blaho VA, Hla T. Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors[J]. Chemical Reviews, 2011, 111:6299-6320. [16] Harma V, Knuuttila M, Virtanen J, et al. Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models[J]. Oncogene, 2012, 31:2075-2089. [17] Matsumoto T, Kobayashi T, Kamata K. Role of lysophosphatidylcho-line(LPC)in atherosclerosis[J]. Current Medicinal Chemistry, 2007, 14(30):3209-3220. [18] Meyer zu Heringdorf D, Jakobs KH. Lysophospholipid receptors:signalling, pharmacology and regulation by lysophospholipid metabolism[J]. Biochim Biophys Acta, 2007, 1768(4):923-940. [19] Kitayoshi M, Fukui R, Tanabe E, et al. Different effects on cell proliferation and migration abilities of endothelial cells by LPA1 and LPA3 in mammary tumor FM3A cells[J]. Journal of Receptor and Signal Transduction Research, 2012, 32(4):209-213. [20] Gerrard JM, Robinson P. Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin[J]. Biochim Biophys Acta, 1989, 1001(3):282-285. [21] Bandoh K, Aoki J, Taira A, et al. Lysophosphatidic acid(LPA)receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors[J]. FEBS Letters, 2000, 478(1-2):159-165. |